- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00788593
A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 (APT-1008) in Chronic Pancreatitis (CP) Participants With Exocrine Pancreatic Insufficiency (EPI)
A Randomized, Double-Blind, Dose Response-Control, Crossover Study to Evaluate the Safety and Efficacy of Two Doses of EUR-1008 in Chronic Pancreatitis (CP) Patients With Exocrine Pancreatic Insufficiency (EPI)
Study Overview
Status
Intervention / Treatment
Detailed Description
After screening, eligible participants will start the placebo baseline ambulatory phase (4 days). On day 5, they will be hospitalized for three to five days, to undergo a "baseline" 72-hour CFA determination under a controlled diet and using a stool marker to indicate the beginning and end of the controlled diet period, while they continue receiving placebo treatment. At the end of the placebo baseline phase, participants will be randomized to a "high dose followed by a low dose" or to a "low dose followed by a high dose" EUR-1008 (APT-1008) dose sequence and proceed to the first crossover (treatment) phase. Each crossover (treatment) phase will consist of a stabilization period for six days at home, followed by a hospitalization of three to five days to undergo a 72-hour CFA determination using a controlled diet and using a stool marker to indicate the beginning and end of the controlled diet period.
Participants will immediately proceed from the first crossover (treatment) phase to the second without a washout period or return-to-baseline period in between phases. Participants will be stabilized at home for 6 days. Any residual lipase from the prior treatment phase is likely to be a negligible influence on the subsequent CFA determination because participants will be taking the new dose level (high or low) for six days before the beginning of sample collection for a new CFA. This interval is more than enough time for the CFA to be reflective of only the new dose.
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Bologna
-
Massarenti, Bologna, Italy, 9-40138
- Dipartmento di Malattie dell' apparato digerente e Medicina Interna- Unita Operativa di MedicinaInterna Corinaldesi Azienda Ospedaliero- Universitaria Policlinico Sant'Orsola Malpighi Via Massarenti
-
-
Milano
-
Rozzano, Milano, Italy, 20089
- Istituto Clinico Humanitas - Universita' Di Milano Via Manzoni
-
-
Roma
-
Largo Agostino Gemelli, Roma, Italy, 8 00168
- Istituto di Clinica Chirurgica (Ensoscopia Digestive Chirurgica) Policlinico Gemelli-Universita Cattolica del Sacro Cuore
-
-
Verona
-
le Ludovico Scuro, Verona, Italy, 10 37134
- Centro Richerche Cliniche di Verona
-
-
-
-
-
Donetsk, Ukraine, 83017
- Department of Internal Medicine No 2 of Donetsk State University named after M. Gorkly, City Clinical Hospital No 3
-
-
Crimea
-
Simferopol, Crimea, Ukraine, 95017
- Department of Therapy and Family Medicine of the Facility of Post graduate Education of Crimea State Medical University named after S.I. Georglyevskyy Republic Clinical Hospital named after M.O. Semashko
-
-
Kharklv
-
Kharkiv, Kharklv, Ukraine, 61039
- Department of Liver and Gastrointestinal Tract Disease Institute of Therapy named after L.T. Maylaya of Academy of Medical Sciences of the Ukraine
-
-
Kylv
-
Kyiv, Kylv, Ukraine, 01030
- Department of Faculty Therapy No 1 with the Course of Postgraduate Training of Physicians for Gastroenterology and Endoscopy, National Medical University named after O.O. Bogomolets, City Hospital No 18
-
Kyiv, Kylv, Ukraine, 01133
- General Therapy Clinic, Military Clinical Hospital of Ministry of Defense of Ukraine 18
-
-
-
-
Arkansas
-
Little Rock, Arkansas, United States, 72211
- Woodland International Research Group
-
-
California
-
Los Angeles, California, United States, 90015
- HealthCare Partners Medical Group
-
-
Florida
-
Gainesville, Florida, United States, 32610
- University of Florida, General Clinical Research Center
-
Port Orange, Florida, United States, 32127
- Advanced Medical Research Center
-
-
Illinois
-
Hines, Illinois, United States, 60141
- Veterans Affairs Edward Jr. Hines Hospital, Building #1
-
-
Iowa
-
Iowa Ctiy, Iowa, United States, 52242
- University of Iowa Hospitals and Clinics
-
-
Kentucky
-
Lexington, Kentucky, United States, 40536
- University of Kentucky, Medical Center, Department of Gastroenterology
-
Louisville, Kentucky, United States, 40202
- University of Louisville, Carmichael Building
-
-
Missouri
-
Columbia, Missouri, United States, 65212
- University of Missouri Health Care
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Participants are male or female
- Participants with age over 18 years
- Participants who have written, legally valid informed consent
- Women of childbearing potential must be using a medically acceptable form of birth control for the 30 days prior to the beginning of the study and agree to maintain adequate birth control measures during the whole duration of the study plus an additional 30 days as well as have a negative pregnancy test at screening Visit 3 and Visit 7
- Participants with documented diagnosis of CP by medical history and it is preferred that it is supported by imaging evidence confirming CP which include: abnormal endoscopic retrograde cholangio-pancreatography (ERCP) (Cambridge Class 4), abnormal computed tomography (CT) scan (dilated main pancreatic duct, atrophy of the pancreas or calcification), abnormal ultrasound, or endoscopic ultrasound with at least 5 abnormalities noted
- In the case of pancreatic surgery, the participant can be included with partial or distal resection of the pancreas (not due to cancer)
- Participants with documented EPI with target fecal elastase (FE) less than or equal to 100 microgram per gram (mcg/g) of stool using the monoclonal test (pancreatic elastase 1 [PE1] by Genova Diagnostics) performed at the screening visit. The mean coefficient of variation (CV) for the FE test is 20 percent (%)
Exclusion Criteria:
- Participants known to the investigator to have a significant medical and/or mental disease that would compromise the participant's welfare, pose an unacceptable risk to him/her or confound the study results
- Participants who participated in a clinical trial within 30 days of randomization or per specific country regulations/guidelines
- Participants with cystic fibrosis
- Participants with excessive alcohol consumption
- Participants with drug abuse
- Participants with contraindicated medications or who are unable to discontinue prohibited concomitant medication
- Participants with uncontrolled diabetes mellitus
- Participants allergic to pork protein/unwilling to ingest pork products
- Participants with atopic predisposition such as multiple drug hypersensitivity, allergic asthma, urticaria, or other relevant allergic diathesis
- Participants who are pregnant or lactating
- Participants with acute pancreatitis or acute exacerbation in chronic pancreatitis
- Participants with acute biliary disease
- Participants with malabsorption syndrome caused by a metabolic disease or by surgery, not related to exocrine pancreatic insufficiency
- Participants with any resection of the stomach or the gastrointestinal tract that will affect transit time and/or gastric emptying.
- Participants with evidence of active gastric or duodenal ulcer
- Participants with chronic inflammatory bowel disease
- Participants with any history of pancreatic cancer and other non-cutaneous malignancies (except basal cell and squamous cell carcinoma of the skin in situ that have been removed and not reoccurred in 5 years)
- Participants with viral hepatitis with infectious virions in blood and/or body fluids (any etiology)
- Participants with human immunodeficiency virus (HIV) infection
- Participants with hyperuricemia ( greater than [>] 1.5 times upper normal value for lab)
- Participants with any acute or chronic disease, which in the opinion of the investigator could influence study results or pose a risk to the participants' safety
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: Placebo
|
Placebo matching to EUR-1008 (APT-1008) capsules orally daily for 4 days home treatment and 3 to 5 days hospital treatment in the baseline run-in phase, which will then be randomized to either high dose or low dose of EUR-1008 (APT-1008).
|
Experimental: EUR-1008 (APT-1008) High Dose
|
EUR-1008 (APT-1008) total high dose 140,000 lipase USP Lipase units will be given as 7 capsules containing 20,000 USP Lipase units each, orally daily, distributed over the day per gram of fat in diet (possible example: 2 capsules with breakfast, 2 capsules with lunch, 2 capsules with dinner and 1 capsule with a snack) for 6 days home treatment and 3 to 5 days hospital treatment in either first intervention period or second intervention period.
Other Names:
|
Experimental: EUR-1008 (APT-1008) Low Dose
|
EUR-1008 (APT-1008) total low dose 35,000 lipase USP Lipase units will be given as 7 capsules containing 5,000 USP Lipase units each, orally daily, distributed over the day per gram of fat in diet (possible example: 2 capsules with breakfast, 2 capsules with lunch, 2 capsules with dinner and 1 capsule with a snack) for 6 days home treatment and 3 to 5 days hospital treatment in either first intervention period or second intervention period.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent Coefficient of Fat Absorption (CFA) of Participants Treated With High Dose EUR-1008 and Low Dose EUR-1008
Time Frame: 3 to 5 days of hospital treatment in first and second intervention periods
|
Percent CFA was calculated as ([fat intake - fat excretion]/fat intake)*100, determined in the stools collected during the 72-hour CFA determination period.
Mean percent CFA was calculated for the 3 to 5 days of hospital treatment in first and second intervention periods.
|
3 to 5 days of hospital treatment in first and second intervention periods
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Change From Placebo Baseline in Percent Coefficient of Fat Absorption (CFA) in High Dose EUR-1008 and Low Dose EUR-1008 During Hospital Treatment
Time Frame: Baseline, 3 to 5 days of hospital treatment in first and second intervention periods
|
Percent CFA was calculated as ([fat intake - fat excretion]/fat intake)*100, determined in the stools collected during the 72-hour CFA determination period.
Mean percent CFA was calculated for 3 to 5 days of hospital treatment in first and second intervention periods.
|
Baseline, 3 to 5 days of hospital treatment in first and second intervention periods
|
Change From Placebo Baseline in Percent Coefficient of Nitrogen Absorption (CNA) During Hospital Treatment
Time Frame: Baseline, 3 to 5 days of hospital treatment in first and second intervention periods
|
Percent CNA was calculated as [(nitrogen intake - nitrogen excretion)/nitrogen intake]*100 , determined in the stools collected during the 72-hour CNA determination period.
Nitrogen intake was calculated as protein intake/6.2.
Nitrogen excretion was measured as total fecal nitrogen.
Mean percent CNA was calculated for 3 to 5 days of hospital treatment in first and second intervention periods.
|
Baseline, 3 to 5 days of hospital treatment in first and second intervention periods
|
Change From Placebo Baseline in Weight at End of Each Treatment Period
Time Frame: Baseline, end of treatment (6 days home treatment and 3-5 days hospital treatment in first and second intervention periods)
|
Mean change from baseline in weight was calculated for end of treatment (6 days home treatment and 3-5 days hospital treatment) in first and second intervention periods.
|
Baseline, end of treatment (6 days home treatment and 3-5 days hospital treatment in first and second intervention periods)
|
Change From Placebo Baseline in Body Mass Index (BMI) at End of Treatment
Time Frame: Baseline, end of treatment (6 days home treatment and 3-5 days hospital treatment in first and second intervention periods)
|
BMI was calculated by weight divided by height squared and measured as kilogram per square meter (kg/m^2).
Mean change from baseline in BMI was calculated for end of treatment (6 days home treatment and 3-5 days hospital treatment) in first and second intervention periods.
|
Baseline, end of treatment (6 days home treatment and 3-5 days hospital treatment in first and second intervention periods)
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PR-002
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Chronic Pancreatitis
-
Changhai HospitalUnknownChronic Pancreatitis | Idiopathic Chronic PancreatitisChina
-
Postgraduate Institute of Medical Education and...Completed
-
Dartmouth-Hitchcock Medical CenterCompleted
-
The Cleveland ClinicChiRhoClin, Inc.; The National Pancreas FoundationCompletedChronic PancreatitisUnited States
-
Massachusetts General HospitalTerminatedChronic PancreatitisUnited States
-
Winthrop University HospitalCelgene CorporationTerminatedChronic Pancreatitis
-
AbbottCompletedExocrine Pancreatic Insufficiency, Chronic PancreatitisJapan
-
CorEvitasNestle Health ScienceRecruitingChronic PancreatitisUnited States
-
Kangen Pharmaceuticals, IncCompletedChronic PancreatitisUnited States, Russian Federation, Ukraine
Clinical Trials on Placebo
-
SamA Pharmaceutical Co., LtdUnknownAcute Bronchitis | Acute Upper Respiratory Tract InfectionKorea, Republic of
-
National Institute on Drug Abuse (NIDA)CompletedCannabis UseUnited States
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyCompletedMale Subjects With Type II Diabetes (T2DM)Germany
-
Heptares Therapeutics LimitedCompletedPharmacokinetics | Safety IssuesUnited Kingdom
-
GlaxoSmithKlineCompletedPulmonary Disease, Chronic ObstructiveUnited Kingdom, Netherlands
-
Shijiazhuang Yiling Pharmaceutical Co. LtdXuanwu Hospital, BeijingCompleted
-
ItalfarmacoCompletedBecker Muscular DystrophyNetherlands, Italy
-
GlaxoSmithKlineCompletedInfections, BacterialUnited States
-
West Penn Allegheny Health SystemCompletedAsthma | Allergic RhinitisUnited States